5 Value Stocks In The Healthcare Sector
What Defines a Value Stock?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.
The following stocks are considered to be notable value stocks in the healthcare sector:
Genesis Healthcare (NYSE: GEN) - P/E: 1.79
Vanda Pharmaceuticals (NASDAQ: VNDA) - P/E: 4.73
XBiotech (NASDAQ: XBIT) - P/E: 1.0
Salarius Pharmaceuticals (NASDAQ: SLRX) - P/E: 1.74
Jaguar Health (NASDAQ: JAGX) - P/E: 0.09
Genesis Healthcare’s earnings per share for Q1 sits at 0.28, whereas in Q4, they were at -0.1. Genesis Healthcare does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
This quarter, Vanda Pharmaceuticals experienced a decrease in earnings per share, which was 0.08 in Q4 and is now 0.01. Vanda Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
XBiotech has reported Q4 earnings per share at -0.63, which has decreased by 320.0% compared to Q3, which was -0.15. XBiotech does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Salarius Pharmaceuticals has reported Q1 earnings per share at -0.22, which has increased by 50.0% compared to Q4, which was -0.44. Salarius Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
Jaguar Health saw an increase in earnings per share from -1.62 in Q4 to -0.56 now. Jaguar Health does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
